| Archived Releases |
 |
Biodel Regains Compliance with NASDAQ Minimum Bid Price Listing Requirement
Jun 27, 2012
|
9.8 KB |
|
| |
DANBURY, Conn., June 27, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has received notice from the NASDAQ Stock Market that the Company has regained compliance with The NASDAQ Stock Market Listing Rules that require maintenance of a minimum $1.00 bid price. As a result, the Company's common stock will continue to be list...
|
|
Biodel Announces $18.5 Million Private Placement
Jun 22, 2012
|
11.8 KB |
|
| |
DANBURY, Conn., June 22, 2012 /PRNewswire/ -- Biodel Inc. (NASDAQ: BIOD) today announced that it has entered into a definitive securities purchase agreement with a group of institutional investors, including both existing and new investors, for the private placement of approximately 7.9 million shares of its capital stock and warrants to purchase a...
|
|
Biodel Announces Effectiveness of Reverse Stock Split
Jun 11, 2012
|
13.2 KB |
|
| |
DANBURY, Conn., June 11, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today announced that its Board of Directors has approved a reverse split of its common stock (the "Reverse Stock Split") at a ratio of one-for-four. The Company's common stock will begin trading on a split-adjusted basis when the NASDAQ Capital Market opens on June 12, 2012...
|
|
Biodel Obtains Exclusive License to Aegis Therapeutics' Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
Jun 8, 2012
|
14.0 KB |
|
| |
DANBURY, Conn., June 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) and Aegis Therapeutics, LLC (Aegis) today announced a partnership providing Biodel an exclusive worldwide license to Aegis' proprietary ProTek® and Intravail® technologies for the development and commercialization of pharmaceutical formulations of glucagon. ProTek...
|
|
Biodel Announces Data Presentations at American Diabetes Association Annual Meeting
Jun 5, 2012
|
13.1 KB |
|
| |
DANBURY, Conn., June 5, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will present data from animal and human studies with its ultra-rapid-acting prandial insulin product candidates during the 72nd Scientific Sessions of the American Diabetes Association being held in Philadelphia, PA from June 8 to June 12. The data to be presented demonstrates...
|
|
Biodel Announces Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
May 10, 2012
|
11.5 KB |
|
| |
DANBURY, Conn., May 10, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that NASDAQ has approved the Company's request to voluntarily transfer the listing of its shares of common stock from The NASDAQ Global Market to The NASDAQ Capital Market. The transfer will be effective at the opening of business on May 11, 2012 and the Compan...
|
|
Biodel Reports Second Quarter Fiscal Year 2012 Financial Results
May 10, 2012
|
20.7 KB |
|
| |
DANBURY, Conn., May 10, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the second fiscal quarter ended March 31, 2012.
Highlights since Beginning of Second Fiscal Quarter
Announced a planned New Drug Application (NDA) submission by the first calendar quarter of 2014 for a proprietary glucagon...
|
|
Biodel to Report Second Quarter Fiscal Year 2012 Financial Results on May 10, 2012
May 7, 2012
|
8.7 KB |
|
| |
DANBURY, Conn., May 7, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year 2012 financial results on May 10, 2012. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
...
|
|
Biodel's Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
May 2, 2012
|
11.5 KB |
|
| |
DANBURY, Conn., May 2, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) announced today that it has received a notice of allowance from the European Patent Office for patent claims covering Biodel's ultra-rapid-acting insulin formulations intended for the treatment of patients with diabetes. The allowed claims cover formulations containing insulin ...
|
|
Ms. Julia R. Brown and Mr. Davey S. Scoon Join Biodel Board of Directors
Apr 26, 2012
|
13.9 KB |
|
| |
DANBURY, Conn., April 26, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced the appointments of Ms. Julia R. Brown and Mr. Davey S. Scoon to its Board of Directors. The company also announced that Mr. Donald M. Casey has resigned from the Board to attend to his recent appointment as Chief Executive Officer (CEO) of Cardinal Health's ...
|
|
Biodel Reports Positive Top-Line Results from Study of Experimental Ultra-Rapid-Acting Insulin Formulations
Apr 15, 2012
|
18.8 KB |
|
| |
DANBURY, Conn., April 15, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced positive top-line results from a Phase 1 clinical trial of its product candidates, BIOD-123 and BIOD-125 -- two proprietary ultra-rapid-acting formulations of recombinant human insulin (RHI).
BIOD-123 and BIOD-125 achieved the Company's target phar...
|
|
Biodel to Provide Update on Stabilized Glucagon Program at ROTH Conference Today
Mar 14, 2012
|
12.3 KB |
|
| |
DANBURY, Conn., March 14, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today will provide an update on its stabilized glucagon program at the ROTH 24th Annual OC Growth Stock Conference in Laguna Niguel, California. This presentation will be webcast at 5:00 p.m. EDT (2:00 p.m. PDT).
The company recently received feedback from the FDA rega...
|
|
Biodel Inc. to Present at ROTH 24th Annual OC Growth Stock Conference on March 14th, 2012
Mar 8, 2012
|
8.5 KB |
|
| |
DANBURY, Conn., March 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the ROTH 24th Annual OC Growth Stock Conference on March 14, 2012 at 3:00 p.m. Pacific Time (6:00 p.m. Eastern Time). ...
|
|
Biodel Reports First Quarter Fiscal Year 2012 Financial Results
Feb 8, 2012
|
19.5 KB |
|
| |
DANBURY, Conn., Feb. 8, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the first quarter ended December 31, 2011.
Dr. Errol De Souza, president and chief executive officer of Biodel, stated: "Based on our work last quarter, we have advanced our new ultra-rapid-acting recombinant human insulin candidates in...
|
|
Biodel to Report First Quarter Fiscal Year 2012 Financial Results on February 8, 2012
Feb 3, 2012
|
8.8 KB |
|
| |
DANBURY, Conn., Feb. 3, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2012 financial results on February 8, 2012. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
...
|
|
Committee for Orphan Medicinal Products Recommends Orphan Designation for Biodel's Stabilized Glucagon for the Treatment of Congenital Hyperinsulinism
Jan 20, 2012
|
13.4 KB |
|
| |
DANBURY, Conn., Jan. 20, 2012 (GLOBE NEWSWIRE) -- Biodel Inc. (Nasdaq:BIOD) today reported that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has recommended that Biodel's Stabilized Glucagon for the treatment of congenital hyperinsulinism (CHI) be granted Orphan Medicinal Product Designation. The COMP's recom...
|
|
Biodel Inc. to Present at 30th Annual JPMorgan Healthcare Conference on January 12th, 2012
Jan 6, 2012
|
8.5 KB |
|
| |
DANBURY, Conn., Jan. 6, 2012 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Errol De Souza, President and CEO of Biodel, will present a corporate update at the 30th Annual JPMorgan Healthcare Conference on Thursday, January 12, 2012 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time).
The JPMorgan Healthcare Conference w...
|
|
Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Dec 6, 2011
|
21.0 KB |
|
| |
DANBURY, Conn., Dec. 6, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the fourth quarter ended September 30, 2011.
Fourth Quarter Operating Highlights
During Biodel's fourth quarter of fiscal year 2011, the company:
Selected a new lead candidate formulation of ultra-rapid-acting recombinant human in...
|
|
Biodel to Report Fourth Quarter Fiscal Year 2011 Financial Results on December 6, 2011
Dec 1, 2011
|
8.9 KB |
|
| |
DANBURY, Conn., Dec. 1, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter fiscal year 2011 financial results on December 6, 2011. Following the release of the company's financial results, Biodel's senior management will host a conference call to discuss the results and provide an update on the company's progress.
...
|
|
Biodel Reports Top-Line Results From Pump Study of Experimental Insulins
Sep 27, 2011
|
10.4 KB |
|
| |
DANBURY, Conn., Sept. 27, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today announced top-line results from a Phase 1 clinical trial of BIOD-105 and BIOD-107 at Oregon Health and Sciences University to evaluate the pharmacokinetic, pharmacodynamic and infusion site tolerability profiles of these ultra-rapid-acting formulations of recombinant hu...
|
|
|
